NCT00003819View on ClinicalTrials.gov

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 1998

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

QS21

BIOLOGICAL

TF(c)-KLH conjugate vaccine

BIOLOGICAL

Thomsen-Friedenreich antigen

BIOLOGICAL

keyhole limpet hemocyanin

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00003819 - Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer | Biotech Hunter | Biotech Hunter